We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Dizal Pharmaceutical

News List

Easier to produce COVID vaccine shows promise in trials; nasal spray vaccine booster works in mice FirstWordPharma
January 29, 2022
Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation to DZD9008 (Sunvozertinib) for the treatment of patients...
FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion prnasia
January 28, 2022
Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation to DZD9008 (Sunvozertinib) for the treatment...
AstraZeneca, Chinese FIIF establish joint venture Dizal Pharmaceutical in China pharmaasia
November 30, 2017
Collaboration aims to accelerate local development of innovative medicines for patients in China and builds on AstraZeneca’s strong presence in the country